What the trial was testing
The InnovaTV 201 enrolled 195 patients with solid tumors. The study was sponsored by Seagen and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was an early-stage trial — researchers are still confirming safety and getting an early look at how well the treatment works. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
16% tumor response rate across heavily pretreated solid tumors.
The Lancet Oncology · 2019 · NCT02001623
These findings — that across multiple advanced solid tumors in this first-in-human dose-finding study — were published in the The Lancet Oncology and represent the headline result of the study.
Researchers tracked outcomes across 195 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with solid tumors, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Tisotumab vedotin (Tivdak) is FDA-approved for advanced cervical cancer that has progressed after chemotherapy and is available now. Eye-related side effects are notable and require an eye care plan during treatment. Ask a gynecologic oncologist if it fits your case.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open solid tumors trials
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.